共 50 条
- [41] Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041 Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment? [J]. EUROPEAN UROLOGY, 2018, 73 (03) : E74 - E74
- [42] Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007 [J]. EUROPEAN UROLOGY, 2014, 66 (04) : E69 - E70
- [43] Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014 [J]. EUROPEAN UROLOGY, 2015, 68 (02) : E31 - E32
- [44] Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.019 A Storm in a Teacup [J]. EUROPEAN UROLOGY, 2022, 81 (05) : E115 - E116
- [46] Reply to Gianluca Giannarini, Nazareno Suardi and Alberto Briganti's Letter to the Editor re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al. A Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22 393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.11.018 [J]. EUROPEAN UROLOGY, 2014, 65 (06) : E91 - E92
- [47] Reply to Hiten D. Patel and Mohamad E. Allaf's Letter to the Editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034 [J]. EUROPEAN UROLOGY, 2013, 64 (05) : E107 - E108
- [48] Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo. 2017.03.036 [J]. EUROPEAN UROLOGY, 2017, 72 (06) : E157 - E157
- [49] Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042 [J]. EUROPEAN UROLOGY, 2017, 72 (06) : E164 - E165
- [50] Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042 [J]. EUROPEAN UROLOGY, 2017, 72 (04) : E98 - E99